Last reviewed · How we verify
Aclovate (ALCLOMETASONE DIPROPIONATE)
Aclovate (alclometasone dipropionate) is a marketed topical corticosteroid used for treating inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, competing in a crowded market with several off-patent generics and one patent-protected competitor, desonide. Its key strength lies in its mechanism of action, which effectively reduces skin inflammation through glucocorticoid receptor binding, offering a reliable treatment option. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased generic competition and potential revenue erosion.
At a glance
| Generic name | ALCLOMETASONE DIPROPIONATE |
|---|---|
| Sponsor | Fougera Pharms |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Common side effects
- itching
- burning
- erythema
Key clinical trials
- Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (PHASE2)
- Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aclovate CI brief — competitive landscape report
- Aclovate updates RSS · CI watch RSS